EMBOLD

The EMBOLD Study

Hope for children with early-onset SCN2A or SCN8A Developmental and Epileptic Encephalopathies (DEEs)

The EMBOLD study is investigating a new potential treatment for children with early-onset SCN2A or SCN8A DEEs.

See if your child qualifies at www.resiliencestudies.com/embold

About the EMBOLD Study

Purpose

To understand how safe and effective relutrigine is in reducing seizures.

Duration

Up to 22 weeks in the initial study, with the opportunity to continue on treatment for an additional 48 weeks in an open-label extension.

At Home or In Clinic

United States, Europe, United Kingdom

Choose where your child participates in the study, whether at home, in clinic, or a combination of the two.

EMBOLD Study Criteria

- 1 through 18 years of age
- Have received a diagnosis of
  - SCN2A gene mutation with onset of seizures in the first 3 months of life, or
  - SCN8A gene mutation with seizures
- Have at least 8 motor seizures (seizures that involve movement) in the 4 weeks prior to screening

Why should my child participate?

The flexibility to participate at home, in clinic at a study site, or a combination of both.

Travel and/or relocation assistance are available. This means lodging, meals, and any other costs associated with study participation will be paid for by the sponsor.

All participants will receive relutrigine during the study at some point.

Your child may be able to continue on relutrigine after the completion of trial participation through an expanded access program after the open-label extension.

About Relutrigine

Relutrigine is an investigational medicine that can be taken orally or administered through G/J tube. Relutrigine is designed to regulate sodium flow in brain cells by targeting overactive sodium channels that cause seizures, therefore potentially offering better seizure control with fewer side effects. Relutrigine has been designed to maximize its effects against overactive sodium channels that are believed to cause seizure activity while minimizing the blocking of normal activity needed for healthy brain function.

Is EMBOLD right for your child?

See if your child qualifies at www.resiliencestudies.com/embold

PRAX-562-221 Advarra IRB: MOD02573757